Smith & Nephew SNATS, Inc. (NYSE:SNN) Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 37.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,590 shares of the medical equipment provider's stock after buying an additional 14,677 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Smith & Nephew SNATS were worth $1,520,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in SNN. Sei Investments Co. raised its holdings in shares of Smith & Nephew SNATS by 229.8% during the fourth quarter. Sei Investments Co. now owns 75,215 shares of the medical equipment provider's stock worth $1,849,000 after purchasing an additional 52,411 shares during the last quarter. Townsquare Capital LLC raised its holdings in shares of Smith & Nephew SNATS by 19.0% during the fourth quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock worth $432,000 after purchasing an additional 2,798 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Smith & Nephew SNATS during the fourth quarter worth $435,000. Barclays PLC purchased a new position in shares of Smith & Nephew SNATS during the fourth quarter worth $431,000. Finally, Principal Securities Inc. raised its holdings in shares of Smith & Nephew SNATS by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 691 shares during the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

SNN traded up $0.04 on Friday, reaching $30.25. The stock had a trading volume of 882,877 shares, compared to its average volume of 817,601. Smith & Nephew SNATS, Inc. has a 12-month low of $23.69 and a 12-month high of $31.72. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62. The business's 50-day moving average price is $28.67 and its two-hundred day moving average price is $27.10. The company has a market cap of $13.25 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 0.93 and a beta of 0.68.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SNN shares. Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. UBS Group cut shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group lifted their price objective on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a report on Thursday, May 1st. Six investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.